Sharemaestro Newsreel

NEO5107997 Bond Profile — Key Metrics

This article provides key metrics for the NEO5107997 bond issued by NeoGenomics, Inc. It details the bond's coupon rate, issue and maturity dates, outstanding amount, and face value. The profile also includes a brief description of NeoGenomics, Inc., a clinical laboratory company specializing in …

Illumina’s CEO Says the Clinical Growth Isn’t a Cliff. Q2 Earnings Back Him Up.

Illumina reported strong Q2 2026 earnings, exceeding revenue and EPS estimates, driven primarily by robust clinical market growth. The company raised its full-year guidance for revenue and EPS, emphasizing the sustained demand for clinical sequencing, particularly with the NovaSeq X platform. TIKR's valuation model …

BLLN (BLLN) holder files to sell 32,500 Class A shares after option exercise

A BLLN holder has filed a Form 144 notice to sell up to 32,500 Class A shares on August 3, 2026, stemming from a stock option exercise, with an aggregate value of $4,488,575.00. The shares are to be sold through Fidelity Brokerage Services LLC …

BLLN issuer: insiders detail planned and recent Class A stock sales (BLLN)

BillionToOne, Inc. (BLLN) filed a Form 144 indicating a planned sale of 12,500 Class A Pre-IPO shares valued at $1,717,125.00 through Fidelity Brokerage Services LLC, with an effective date of August 3, 2026. The filing also disclosed previous Class A share sales by insiders …

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026

Faruqi & Faruqi, LLP reminds investors of the August 3, 2026, deadline to seek lead plaintiff status in a federal securities class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS). The lawsuit alleges that GeneDx and its executives made false and misleading statements regarding …

Revvity earnings in focus: AI fears test life sciences tools maker By Investing.com

Revvity is facing scrutiny ahead of its Q2 earnings report due to investor concerns that AI adoption could reduce demand for its preclinical research tools. Analysts expect modest earnings growth but a revenue decline, with the earnings call likely to address the "AI loser" …

IDEXX earnings on deck: Can innovation sustain growth momentum?

IDEXX Laboratories Inc. is set to report its second-quarter earnings, with investors keen to see if the company can maintain its growth trajectory. Analysts anticipate EPS of $3.96 and revenue of $1.20 billion, driven by strong performance in Companion Animal Group diagnostics and adoption …

Certara earnings up next: Can AI strategy stem revenue decline? By Investing.com

Certara, a biosimulation software provider, is set to report its second-quarter results, with analysts expecting an EPS increase but a 6% revenue decline year-over-year. Investors will be watching whether the company's new leadership and AI-focused strategy, including a partnership with NVIDIA and increased R&D …

Why Myriad Genetics (MYGN) Is Down 49.0% After Cutting 2026 Revenue Outlook On Prenatal Weakness

Myriad Genetics (MYGN) shares dropped 49% after the company cut its 2026 revenue outlook to US$770-790 million, down from US$190.7 million, primarily due to weaker Prenatal Health test volumes. Despite a narrowed net loss, the reduced forecast highlights ongoing pressure on test volumes and …

Barclays Raises Mettler-Toledo International (NYSE:MTD) Price Target to $1,575.00

Barclays has increased its price target for Mettler-Toledo International (NYSE:MTD) to $1,575.00 from $1,300.00, maintaining an "overweight" rating. This new target suggests an 11.03% potential upside from the stock's previous close. The company recently reported strong quarterly earnings, surpassing analyst expectations with $11.46 EPS …

S&P 500 Futures Up in Premarket Trading; GameStop, Twist Bioscience Lag

S&P 500 futures showed an increase in premarket trading. Among individual stocks, Tenet Healthcare Corp. (THC) and Ferguson Enterprises Inc. (FERG) saw significant gains, while GameStop and Twist Bioscience lagged.

Twist Bioscience stock falls 5% on earnings miss despite revenue beat

Twist Bioscience Corporation (NASDAQ:TWST) reported third-quarter fiscal 2026 results with a miss on earnings per share but a beat on revenue expectations, leading to a 4.97% drop in pre-market trading. The company achieved a record revenue of $118.4 million, marking its 14th consecutive quarter …

Press Release: Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results

Twist Bioscience has announced its financial results for the third quarter of fiscal year 2026. The company reported significant revenue growth and provided updates on its operational progress and future outlook. Key highlights include strong performance across its various product lines and strategic advancements …

Cocrystal Pharma Secures $5 Million Investment from OPKO Health as Norovirus Program Advances Toward Phase 1b Data

Cocrystal Pharma has secured a $5 million investment from longtime investor OPKO Health, increasing OPKO's stake in the company. This funding will support Cocrystal's norovirus program, particularly its lead candidate CDI-988, as it advances towards releasing topline data from its Phase 1b clinical trial …

Canaccord cuts Veracyte stock price target to $50 on revenue outlook

Canaccord has lowered its price target for Veracyte (NASDAQ: VCYT) to $50 from $60, while maintaining a Hold rating due to reduced revenue estimates in future years of its DCF model. Despite beating Q2 2026 estimates and increasing 2026 revenue guidance, Veracyte's stock dropped …

Cocrystal Pharma (NASDAQ: COCP) secures $5M investment from OPKO Health

Cocrystal Pharma has secured a $5 million investment from longtime investor OPKO Health through a private placement of 5,474,053 common shares at $0.9134 per share. The biotech company plans to use these proceeds to advance its preclinical and clinical antiviral programs, including its lead …

OPKO Buys 5.47M Cocrystal Shares Ahead of Late-2026 Norovirus Data

OPKO Health has made a $5 million private placement in Cocrystal Pharma, purchasing 5,474,053 common shares at $0.9134 per share. This investment aims to support the advancement of Cocrystal's lead norovirus candidate, CDI-988, with topline Phase 1b data anticipated by the end of the …

CareDx climbs another 9% after guidance raise, sets new 52-week high (CDNA:NASDAQ)

CareDx (CDNA) shares rallied over 9%, extending a previous 15% surge, after the company raised its full-year revenue guidance and reported strong second-quarter results. The precision medicine diagnostics company, focused on transplant patients, reached a new 52-week high. Key drivers include testing services segment …

CLLS|Cellectis SA|Price:2.920|Chg%:+0.170

This article provides a comprehensive stock analysis of Cellectis SA (CLLS) by TradingKey, detailing its financial health, valuation, growth potential, and institutional confidence. The company is described as a France-based genome engineering firm with significant revenue growth and a "Buy" analyst rating despite a …

eyeQ: Burberry, M&G, Shell, Thermo Fisher Scientific

This article from eyeQ uses its smart machine to identify 10 UK and 10 international stocks that are either undervalued or overvalued compared to their Model Value, based on current macro conditions. It details companies like Burberry and Thermo Fisher Scientific, highlighting their Fair …

CareDx Deadline Alert

Faruqi & Faruqi, LLP is investigating potential claims against CareDx Inc. (NASDAQ: CDNA) and reminds investors of the July 22, 2022 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that CareDx engaged in improper schemes …

353 Wisconsin workers received layoff notices from 6 companies in July

In July, 353 workers across six Wisconsin companies received layoff notices due to facility closures and financial unsustainability. Despite these layoffs, Wisconsin's unemployment rate slightly decreased to 3.3%, and labor force participation rose to 64.5%. Companies like School Specialty, Prairie Farms Dairy, Centers for …

Agilent Technologies, Inc. (A) Stock Analysis: Evaluating a 15% Potential Upside Amidst a Robust Revenue Growth

RadNet, Inc. (RDNT) Investor Outlook: A 40% Potential Upside In Healthcare Imaging

RadNet, Inc. (RDNT), a key player in diagnostic imaging, shows significant growth potential driven by its innovative integration of AI technologies like DeepHealth OS. Analysts are overwhelmingly positive, projecting a 40.72% upside with an average target price of $89.75. Despite a negative EPS and …

Wells Fargo Adjusts PT on Mettler-Toledo International to $1,450 From $1,225, Keeps Equalweight Rating

Wells Fargo has increased its price target for Mettler-Toledo International (MTD) to $1,450 from $1,225, while maintaining an Equalweight rating on the stock. This adjustment comes amidst recent analyst actions, with other firms like Morgan Stanley, Stifel, and Goldman Sachs also updating their price …

Waters Corporation $WAT Stock Holdings Increased by Edgestream Partners L.P.

Thermo Fisher Patches Flaw That Could Make DNA File Tampering Nearly Undetectable

Thermo Fisher Scientific has patched a critical flaw (CVE-2026-17583) in its Applied Biosystems human identification software that could allow nearly undetectable tampering of DNA data files. The vulnerability, rated High with a CVSS v4.0 score of 8.2, could enable malicious actors with server access …

Danaher: CEO Change Comes Amid Challenging Times for Company

Danaher announced a CEO transition from Rainer Blair to Julie Sawyer Montgomery, a diagnostics leader, on August 3. Shares rose about 2% in after-hours trading following this news. This change comes as the company faces challenging times, including bioprocessing delays mentioned in recent analyst …

IQVIA Holdings, Inc. Stock 12‑Month Price Target Raised to $275, Implies 17% Upside

IQVIA Holdings, Inc. (IQV) has seen its average 12-month price target raised to $275 by 17 analysts, up from $272.65. This new target implies a potential upside of approximately 17% from its July 31 closing price. The consensus rating for IQV remains a "Buy" …

BTIG Research Forecasts Strong Price Appreciation for Castle Biosciences (NASDAQ:CSTL) Stock

GeneDx Holdings (Nasdaq: WGS) grows Q2 2026 revenue to $114.4M amid GAAP loss

Twist Bioscience Shares Decline Following Quarterly Earnings Miss

Twist Bioscience (NASDAQ:TWST) Posts Earnings Results, Misses Estimates By $0.07 EPS

Twist Bioscience (NASDAQ:TWST) Shares Gap Down on Disappointing Earnings

Twist Bioscience (TWST) Earnings Date and Reports 2026 $TWST

Twist Bioscience (TWST) Reports Q3 Loss, Beats Revenue Estimates